It leverages Kite’s Chimeric Antigen Receptors and Appia Bio’s Allogeneic Cell Technology Platform to Develop Off-the-Shelf Cell Therapies
By 2022, 150,000 primary health care centres would be in place in rural as well as urban areas
CDSCO to fast-track trials and approval for COVID19 vaccine
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
EPS climbs to Rs 9.25 for the quarter
AstraZeneca, Sinopharm and Moderna were part of the study
The scheme incentivizes the manufacturing of patented drugs and other high value drugs at an incentive rate of 10% of incremental sales
The company posted net profit of Rs.19.36 crores for the period ended June 30, 2020.
It works as an adjunct to standard care based on robust clinical trials
Subscribe To Our Newsletter & Stay Updated
